{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"7 cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format."},"pointOfContact":{"email":"DunleavK@mail.nih.gov","organization":"National Cancer Institute","phone":"301-435-1007","title":"Dr. Kieron Dunleavy"}}